---
title: "LifeTech Scientific Delivers Revenue Growth but Profit Hit by Non-Recurring Charges in 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281140579.md"
description: "LifeTech Scientific Corporation reported a 5.1% revenue growth to RMB1,369.8 million for 2025, driven by increased stent graft sales. However, net profit fell 33.3% to RMB112.4 million due to higher expenses and tax charges. Excluding non-recurring items, underlying net profit rose 24.9% to RMB353.4 million. The company did not declare a final dividend, focusing on reinvestment. The latest analyst rating for the stock (HK:1302) is a Hold with a price target of HK$2.00."
datetime: "2026-03-31T04:40:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281140579.md)
  - [en](https://longbridge.com/en/news/281140579.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281140579.md)
---

# LifeTech Scientific Delivers Revenue Growth but Profit Hit by Non-Recurring Charges in 2025

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

LifeTech Scientific Corporation ( (HK:1302) ) has provided an update.

LifeTech Scientific Corporation, a Hong Kong-listed medical device maker specializing in cardiovascular and endovascular products such as stent grafts, reported modest top-line growth for 2025 driven primarily by higher stent graft sales. The group maintains a strong gross margin profile, reflecting the continued strength of its core implantable device franchise in China.

For the year ended 31 December 2025, revenue rose 5.1% to RMB1,369.8 million and gross profit increased 3.8% to RMB1,019.1 million, but reported net profit fell 33.3% to RMB112.4 million as higher share-based payment expenses, increased income tax charges and fair-value losses on financial liabilities weighed on earnings. Excluding non-recurring items, underlying net profit climbed 24.9% to RMB353.4 million, yet earnings per share declined to RMB3.4 basic and the board again opted not to declare a final dividend, signaling a continued focus on reinvestment and cost of incentive schemes over near-term shareholder payouts.

The most recent analyst rating on (HK:1302) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.

**More about LifeTech Scientific Corporation**

LifeTech Scientific Corporation is a Cayman Islands-incorporated medical device company listed in Hong Kong, focusing on cardiovascular and endovascular therapies. The group generates most of its revenue from stent grafts and related implantable devices, with manufacturing and core operations centered in mainland China, including its key subsidiary Lifetech Scientific (Shenzhen) Co., Ltd.

**Average Trading Volume:** 16,564,961

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$7.43B

Find detailed analytics on 1302 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [01302.HK](https://longbridge.com/en/quote/01302.HK.md)
- [159883.CN](https://longbridge.com/en/quote/159883.CN.md)
- [562600.CN](https://longbridge.com/en/quote/562600.CN.md)

## Related News & Research

- [Broncus shareholders back all AGM resolutions, update articles of association](https://longbridge.com/en/news/286439966.md)
- [Trillion-dollar Samsung faces a battle over who gets the AI profits](https://longbridge.com/en/news/287013238.md)
- ['Wait for It,' Says Top Investor About Intel Stock](https://longbridge.com/en/news/286979374.md)
- [India's lifeline ferry across strategic archipelago](https://longbridge.com/en/news/286716580.md)
- [LifeTech Seeks More Time to Restore Independent Board Compliance](https://longbridge.com/en/news/284027617.md)